Replimune Group saw no growth in patent filings and highest growth of 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Replimune Group’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Replimune Group has been focused on protecting inventions in China(CN) with one publication in Q2 2024
The China(CN) Patent Office dominates the patent grants with nearly 100% of grants. The Denmark(DK), and China(CN) patent Office are among the top ten patent offices where Replimune Group is filings its patents. Among the top granted patent authorities, Replimune Group has 100% of its grants in China(CN).
Roche could be the strongest competitor for Replimune Group
Leukemia related patents lead Replimune Group portfolio followed by liver cancer, and oral cavity (mouth) cancer
Replimune Group has highest number of patents in leukemia followed by liver cancer, oral cavity (mouth) cancer, salivary gland cancer, and laryngeal cancer. For leukemia, nearly 2% of patents were filed and 2% of patents were granted in Q2 2024.
For comprehensive analysis of Replimune Group's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
